Figure 6.
![Figure 6. Representative progression of DLBCL negative for CD19 surface expression. (A) Core biopsy shows involvement by DLBCL (hematoxylin-and-eosin [H&E] stain). (B) By immunohistochemistry, the neoplastic B cell strongly expresses B-cell lineage marker CD20 with cell-surface pattern (CD20 immunostain). (C) In contrast, CD19 is only weakly expressed with an exclusively cytoplasmic pattern without surface expression (CD19 immunostain). (A-C) Original magnification ×400.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/134/7/10.1182_blood.2018883421/3/blood883421f6.png?Expires=1735834557&Signature=hTNf57I0OYHNLNvanffM7JehV6pqGYRL7cu5Bdi4BvpavJIixblOiuYIVFLR372cJk3XoBa9ffQaEGNfAPbbvAZ1Ghzr32ByK8I4qEEax9nOjDHQDbUC380a5IZYFAZEjHv2koJO0yzy0SbiiYsPtX6Qkoli5-rbJNGZWXF-sJeng8bJ81oyqxMf7b8sebXtK6HICla4vOH62vV9Wlm70KN79Dj3yLHUekrPRoHRs2UD7owFloi0RogTF-eS5PDXOom4NXHzybrlJpQ9yPTuWnE9MCrVqeF9rFX1FVDVTTROQWCenQY36dvcYFDPlBOQ3BfsDHuIz23vlRByh8BCig__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Representative progression of DLBCL negative for CD19 surface expression. (A) Core biopsy shows involvement by DLBCL (hematoxylin-and-eosin [H&E] stain). (B) By immunohistochemistry, the neoplastic B cell strongly expresses B-cell lineage marker CD20 with cell-surface pattern (CD20 immunostain). (C) In contrast, CD19 is only weakly expressed with an exclusively cytoplasmic pattern without surface expression (CD19 immunostain). (A-C) Original magnification ×400.